- Home
- MRNA vs ABVX Comparison
MRNA vs ABVX Comparison
Compare MRNA & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MRNA | ABVX |
|---|---|---|
| Founded | 2010 | 2013 |
| Country | United States | France |
| Employees | N/A | 67 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.5B | 10.5B |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | MRNA | ABVX |
|---|---|---|
| Price | $55.54 | $109.99 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 12 | 12 |
| Target Price | $33.00 | ★ $128.42 |
| AVG Volume (30 Days) | ★ 9.6M | 733.0K |
| Earning Date | 05-05-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 21.77 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $19,263,000,000.00 | N/A |
| Revenue This Year | $8.28 | N/A |
| Revenue Next Year | $16.53 | $0.22 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 4.29 | N/A |
| 52 Week Low | $22.28 | $4.77 |
| 52 Week High | $59.55 | $148.83 |
Technical Indicators
Market Signals| Indicator | MRNA | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 63.68 | 38.60 |
| Support Level | $23.74 | $107.99 |
| Resistance Level | N/A | $131.27 |
| Average True Range (ATR) | 3.84 | 4.98 |
| MACD | 0.26 | -1.76 |
| Stochastic Oscillator | 69.97 | 14.69 |
Price Performance
Historical ComparisonAbout MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.